The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.
